ANAPTYSBIO, INC
About ANAPTYSBIO, INC
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $234.6M
- Net income
- -$13.2M
- Total assets
- $364.4M
- Market cap
- $1.5B
- Operating margin
- 20.4%
- Net margin
- -5.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $234.6M
- Operating expenses
- $186.7M
- Operating income
- $47.9M
- Income tax
- $164.0K
- Net income
- -$13.2M
- EPS (basic)
- $-0.46
- EPS (diluted)
- $-0.46
Balance sheet
- Total assets
- $364.4M
- Current assets
- $350.2M
- Total liabilities
- $327.2M
- Current liabilities
- $38.6M
- Shareholders’ equity
- $37.2M
Cash flow
- Operating cash flow
- $19.7M
- Investing cash flow
- $228.0M
- Financing cash flow
- -$132.6M
- Net cash flow
- $115.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.5B
- EPS (diluted)
- $-0.46
- Shares outstanding
- 28.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 26, 2017
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $13.2M in FY2025.
- Revenue grew 213% from FY2020 to FY2025.
- Trading 27% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review ANAPTYSBIO, INC.
Write a review
News about ANAPTYSBIO, INC
News & sentiment via Polygon.io
